Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis

Trial Profile

Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2018

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Acronyms PHOENIX-GC
  • Most Recent Events

    • 10 May 2018 Results published in the Journal of Clinical Oncology
    • 07 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Primary endpoint (Overall survival) has not been met according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top